Indication
Autoimmune Diseases
45 clinical trials
58 products
5 drugs
Product
Oral PlaceboClinical trial
A Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Ifetroban in Patients With Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension (SSc-PAH)Status: Recruiting, Estimated PCD: 2025-12-01
Product
IfetrobanClinical trial
A Bioavailability Study of SHR0302 Tablet in Healthy SubjectsStatus: Active (not recruiting), Estimated PCD: 2024-03-01
Product
SHR0302Product
PeresolimabClinical trial
A Phase 2b, Double-Blind, Placebo-Controlled Study to Evaluate Peresolimab in Adult Participants With Moderately-to-Severely Active Rheumatoid ArthritisStatus: Active (not recruiting), Estimated PCD: 2023-11-20
Product
PlaceboProduct
HMPL-523Clinical trial
A Multicenter, Phase 1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523, a Syk Inhibitor, in Adult Subjects With Immune ThrombocytopeniaStatus: Recruiting, Estimated PCD: 2026-04-01
Product
ADI-001Clinical trial
A Phase 1 Study of ADI-001 Anti-CD20 CAR-engineered Allogeneic Gamma-Delta (γδ) T Cells in Adults With Lupus NephritisStatus: Not yet recruiting, Estimated PCD: 2026-12-01
Product
CyclophosphamideProduct
FludarabineClinical trial
A Phase 1, Randomized Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy ParticipantsStatus: Not yet recruiting, Estimated PCD: 2025-04-30
Product
BGB-45035Product
GSK2982772Clinical trial
A Single-centre, Randomized, Double-blind (Sponsor-unblinded), Placebo-controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK2982772 in Repeat Oral Doses in Healthy SubjectsStatus: Completed, Estimated PCD: 2018-10-15
Clinical trial
An Open-Label, First-In-Human Study Evaluating the Safety and Tolerability of VCTX210A Combination Product in Subjects With Type 1 Diabetes Mellitus (T1D)Status: Completed, Estimated PCD: 2023-01-19
Product
VCTX210AClinical trial
An Open-Label, First-in-Human Study Evaluating the Safety, Tolerability, and Efficacy of VCTX211 Combination Product in Subjects With Type 1 Diabetes Mellitus (T1D)Status: Recruiting, Estimated PCD: 2025-04-01
Product
VCTX211Clinical trial
A Single-centre, Randomized, Double-blind, Dose-ascending, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral TID Doses (One Day) of GSK2982772 in Japanese Healthy Male SubjectsStatus: Completed, Estimated PCD: 2018-09-21
Product
DiamydClinical trial
A Phase IIb, 2-Arm, Randomized, Double-blind, Placebo-Controlled, Multicentre Study to Optimize Diamyd Therapy Administered Into Lymph Nodes Combined With Oral Vitamin D to Investigate the Impact on the Progression of Type 1 DiabetesStatus: Completed, Estimated PCD: 2020-07-13
Product
AX-158Product
TacrolimusClinical trial
A Randomised, Double-blind, Placebo-controlled, Study of the Safety, Tolerability, and Pharmacokinetics of AX-158 Following Administration of Single and, Multiple Ascending Oral Doses and Food Effect Sub-study in Healthy Male VolunteersStatus: Completed, Estimated PCD: 2022-11-16
Clinical trial
Efficacy and Safety of 308-nm Excimer Lamp Combined With Tacrolimus vs Tacrolimus as Monotherapy in Treating Vitiligo on ChildrenStatus: Completed, Estimated PCD: 2023-05-01
Product
LPX-TI641Clinical trial
A Phase I First in Human, Randomized, Double-blind, Placebo- Controlled Study in Healthy Adult Volunteers to Evaluate Safety, Tolerability and Pharmacokinetics of LPX-TI641 After Single Oral Doses.Status: Recruiting, Estimated PCD: 2024-04-15
Clinical trial
DiaPrecise, A Phase II Open Label Study to Evaluate the Safety and Feasibility of Intralymphatic Administration of Diamyd® in Individuals at Risk for Type 1 Diabetes Carrying the HLA DR3-DQ2 HaplotypeStatus: Recruiting, Estimated PCD: 2025-02-28
Clinical trial
Biocollection for the Study of Genetic and Immunological Abnormalities in Rare Pediatric-onset Autoimmune and Auto Inflammatory DiseasesStatus: Not yet recruiting, Estimated PCD: 2034-07-01
Clinical trial
A Pilot, Safety and Feasibility Trial of Anti-Thymocyte Globulin (ATG), Low Dose Interleukin-2 (IL-2), Adalimumab and Exenatide in the Treatment of New-Onset Type 1 DiabetesStatus: Withdrawn, Estimated PCD: 2028-12-01
Product
Anti-Thymocyte GlobulinDrug
Interleukin 2Product
ExenatideProduct
AdalimumabClinical trial
Molecular Prediction of Development, Progression or Complications of Kidney, Immune or Transplantation-related DiseasesStatus: Recruiting, Estimated PCD: 2027-09-01
Clinical trial
Etude Multicentrique Internationale rétrospective Des Patients Atteints de déficit Immunitaire associé à la moésine lié au Chromosome X (X Maid Pour X-linked Moesin Associated Immunodeficiency)Status: Recruiting, Estimated PCD: 2026-08-12
Product
Genetic Retrospective StudyClinical trial
SYSTEMS-LEVEL ANALYSES OF IMMUNE DYSREGULATIONStatus: Recruiting, Estimated PCD: 2030-12-31
Product
ImmunomodulationClinical trial
An Exploratory Clinical Study to Evaluate the Safety and Tolerability of F01 in the Treatment of Autoimmune DiseasesStatus: Recruiting, Estimated PCD: 2025-01-01
Product
F01Clinical trial
Personalized Targeted Therapies in Inflammatory Complex Multi Organ DiseaseStatus: Recruiting, Estimated PCD: 2025-11-01
Product
KineretProduct
HumiraProduct
StelaraClinical trial
A Multi-centre, Open-label, Single-group Exploratory Trial of the Safety and Activity of Sparsentan for the Treatment of Incident Patients With Immunoglobulin A NephropathyStatus: Active (not recruiting), Estimated PCD: 2025-03-31
Product
SparsentanProduct
CosentyxProduct
RoactemraDrug
VarlilumabClinical trial
A Phase 1, First-in-human, 2-part Study (Part 1 is a Single Ascending Dose in Healthy Participants; Part 2 is a Multiple Ascending Dose Study in Participants With Autoimmune Disease) to Evaluate the Safety, PD and PK of VIS171Status: Terminated, Estimated PCD: 2024-02-15
Product
VIS171Clinical trial
Multicenter Clinical and Basic Research on the Prevention and Treatment of 2019-nCoV by Integrated Traditional Chinese and Western MedicineStatus: Recruiting, Estimated PCD: 2024-06-01
Product
COVID-19 vaccinesClinical trial
Clinical Study of Targeting CD19-BAFF CAR-T Cells in the Treatment of Autoimmune DiseasesStatus: Recruiting, Estimated PCD: 2027-02-01
Clinical trial
Endometrial Markers in Women With Autoimmune Diseases Receiving Assisted ReproductionStatus: Active (not recruiting), Estimated PCD: 2023-01-31
Product
Endometrial markersClinical trial
Efficacy of Mycophenolate Mofetil Versus Leflunomide as Maintenance Treatment for IgG4-RD Patients With Internal Organ InvolvementStatus: Recruiting, Estimated PCD: 2024-12-31
Product
Mycophenolate MofetilProduct
LeflunomideClinical trial
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other IndicationsStatus: Recruiting, Estimated PCD: 2041-10-01
Clinical trial
Phase I, Open-label, Fast-track Dose-escalation Clinical Trial Exploring the Safety and the Tolerability of Autologous ex Vivo Expanded Regulatory T Cells in Adults With Ulcerative ColitisStatus: Completed, Estimated PCD: 2023-04-12
Product
Regulatory T cellsClinical trial
A Study of Two Different Treatment Strategies in IgG4-related Disease Patients With Re-elevation of Serum IgG4 Level During Maintenance Remission Period: a Randomized Double Blind Placebo Controlled Multicenter StudyStatus: Not yet recruiting, Estimated PCD: 2025-12-01
Drug
placeboClinical trial
Antibiotic Prophylaxis in High-Risk Arthroplasty PatientsStatus: , Estimated PCD: 2025-06-01
Product
CephalexinProduct
DoxycyclineProduct
CefadroxilClinical trial
An Open Label Clinical Trial to Evaluate the Safety and Efficacy of CT103A Cells for the Treatment of Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous SystemStatus: Recruiting, Estimated PCD: 2027-02-22
Product
CT103AClinical trial
An Exploratory Clinical Study of the Safety and Efficacy of CD19 Chimeric Antigen Receptor NK Cell Injections for the Treatment of Relapsed/Refractory B-cell Related Autoimmune DiseasesStatus: Recruiting, Estimated PCD: 2025-03-13
Product
anti-CD19 CAR NK cellsClinical trial
Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of Melatonin Administration in Patients With Multiple Progressive Primary SclerosisStatus: Recruiting, Estimated PCD: 2024-07-01
Product
MelatoninClinical trial
Double-Blind, Randomized, Placebo-Controlled Trial of Naproxen Sodium for the Treatment of Obsessive Compulsive Symptoms in Pediatric Autoimmune Neuropsychiatric Disorder Associated With Streptococcal Infections (PANDAS)Status: Recruiting, Estimated PCD: 2024-10-31
Product
NaproxenClinical trial
Immunomodulatory Effects of Subcutaneous Progesterone in Patients Undergoing IVF Affected by Autoimmune DiseasesStatus: Completed, Estimated PCD: 2017-04-01
Clinical trial
Safety, Activity, and Pharmacology of Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune DiseaseStatus: Terminated, Estimated PCD: 2021-03-18
Drug
T-VECClinical trial
Immune System, Inflammation, Migraine - The Role of Cytokines and Regulatory T Lymphocytes in Migraine PathophysiologyStatus: Not yet recruiting, Estimated PCD: 2027-04-30
Product
Blood testClinical trial
Treatment Strategies for IgG4-RD Patients With Superficial Organ InvolvementStatus: Recruiting, Estimated PCD: 2024-12-30
Product
DiprospanProduct
Diprospan + LeflunomideProduct
Prednisone + LeflunomideClinical trial
Combined Therapy With NB-UVB Phototherapy and Oral Vitamin D Supplementation in Patients With Vitiligo: a Randomized-clinical Trial, Triple-blind, Placebo-controlledStatus: Completed, Estimated PCD: 2022-02-25
Product
Vitamin DClinical trial
JY231 Injection for the Treatment of Refractory Autoimmune Diseases (ADs) Early Exploratory Clinical Studies on Safety, Tolerability, and Initial EfficacyStatus: Not yet recruiting, Estimated PCD: 2026-12-31
Product
JY231Clinical trial
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of ATH-063 in Healthy SubjectsStatus: Completed, Estimated PCD: 2024-02-08
Product
ATH-063Clinical trial
Management of Autoimmune Conditions With Mesenchymal Stem Cells (MSCs) and CAR-T CellsStatus: Recruiting, Estimated PCD: 2027-07-15
Clinical trial
An Exploratory Clinical Study of the Safety and Efficacy of CD19 Chimeric Antigen Receptor NK Cell Injection for the Treatment of Relapsed/Refractory Autoimmune DiseasesStatus: Not yet recruiting, Estimated PCD: 2025-06-30
Product
CD19 CAR NK cells